Pivotal Trial
Definitive clinical study designed to establish safety and effectiveness for marketing authorization.
Definition
A pivotal trial is the primary evidence base for a PMA, De Novo, or PMA Supplement, and increasingly for high-risk MDR submissions. Endpoints are pre-specified, statistical analysis plans are locked, and the study is typically powered for the regulatory hypothesis. Pivotal trials are usually randomized or compared against performance goals, run under an approved IDE in the US, and agreed with FDA through the Q-Submission program before enrollment. Under the EU MDR, they are clinical investigations under Article 62 and Annex XV. Endpoint selection, sample size and analysis population choices are among the most common topics of regulator feedback.What this means in practice
Often preceded by feasibility and EFS studies and followed by post-approval/PMCF studies.Examples
- A medical device manufacturer conducts a randomized controlled pivotal trial to compare the effectiveness of a novel cardiac stent against an already approved device for reducing restenosis rates.
- For a new diagnostic imaging system, a pivotal trial enrolls a large cohort of patients to demonstrate its accuracy and reliability in detecting a specific medical condition compared to current diagnostic standards.
- A company developing an implantable neurostimulation device performs a pivotal study to show its long-term safety and efficacy in managing chronic pain, with pre-specified outcome measures related to pain reduction and quality of life.
- •A common pitfall is conducting a pivotal trial without first establishing a clear statistical analysis plan, which can lead to questions about data integrity and interpretation.
- •Failing to adequately power a pivotal trial for its primary endpoints can result in inconclusive results, necessitating additional studies.
- •Misinterpreting preliminary data from feasibility or early feasibility studies as sufficient for regulatory submission is a frequent mistake.
- •Not addressing potential biases in patient selection or data collection during the trial design phase can undermine the validity of the results.
- •Neglecting to consider the long-term follow-up requirements for certain devices can lead to incomplete data at the time of submission.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsSmall clinical study evaluating initial safety, usability, and design parameters of an investigational device.
FDA authorization to use an investigational device in a clinical study.
FDA program enabling early human evaluation of novel devices with limited preclinical data and iterative design.
Clinical Trials & Evidence
· From this learning pathTrial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.
Any untoward medical occurrence in a subject, whether or not related to the device.
Documented assessment of clinical data demonstrating EU MDR conformity for a device.
Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events.
More in Clinical & Trials
· Same categoryWhere this term appears across MedTech Terms.
- Clinical Trials & EvidenceLesson 14 of 18
Latest in MedTech
Sources
3 sourcesEvery citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 121 CFR Part 812, Investigational Device ExemptionsTier 1 VerifiedeCFRecfr.gov
- 2ISO 14155 Standard PageTier 1 VerifiedISOiso.org
- 3FDA - Clinical Trials and Human Subject ProtectionTier 2 VerifiedFDAfda.gov
Inline markers like [1] jump to the matching reference above.